Filczewski M, Szymańska-Kosmala M
Acta Physiol Pol. 1978 May-Jun;29(3):251-8.
The effect of a new derivative of furanocarboxylic acid MePAF-4 on the arterial blood pressure, heart rate and the concentration of catecholamines in the brain, heart and adrenals was assessed in non-anaesthetised rats. MePAF-4 was given orally in a single dose of 60 mg/kg (1/30 of LD50)administered during 9 days (at the same daily dose), of injected intravenously in a dose of 10 mg/kg. After intravenous injection MePAF-4 had a significant pressor effect associated with bradycardia but without changes in the tissue concentration of catecholamines. After a single oral dose a slight, transient (60 min) rise of the arterial blood pressure was observed, while the heart rate showed no statistically significant changes. Repeated oral administration of MePAF-4 raised the brain dopamine level and adrenal adrenaline level with simultaneous increase in the weight of these organs. No detectable effects of the long term MePAF-4 administration on the arterial blood pressure and heart rate were observed.
在未麻醉的大鼠中评估了呋喃羧酸新衍生物MePAF-4对动脉血压、心率以及脑、心脏和肾上腺中儿茶酚胺浓度的影响。MePAF-4以60 mg/kg的单剂量口服给药(LD50的1/30),持续9天(每日剂量相同),或以10 mg/kg的剂量静脉注射。静脉注射后,MePAF-4具有显著的升压作用并伴有心动过缓,但儿茶酚胺的组织浓度无变化。单次口服给药后,观察到动脉血压有轻微、短暂(60分钟)的升高,而心率无统计学显著变化。重复口服MePAF-4可提高脑多巴胺水平和肾上腺肾上腺素水平,同时这些器官的重量增加。未观察到长期给予MePAF-4对动脉血压和心率有可检测到的影响。